180 Wealth Advisors LLC Has $81,000 Holdings in CalciMedica Inc. $CALC

180 Wealth Advisors LLC lifted its position in shares of CalciMedica Inc. (NASDAQ:CALC) by 207.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,450 shares of the company’s stock after purchasing an additional 34,050 shares during the quarter. 180 Wealth Advisors LLC owned approximately 0.36% of CalciMedica worth $81,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. First Manhattan CO. LLC. acquired a new stake in shares of CalciMedica during the 1st quarter worth approximately $25,000. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of CalciMedica during the 1st quarter worth approximately $45,000. Finally, Wealthedge Investment Advisors LLC grew its holdings in shares of CalciMedica by 289.3% during the 1st quarter. Wealthedge Investment Advisors LLC now owns 108,291 shares of the company’s stock worth $207,000 after purchasing an additional 80,472 shares in the last quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of CalciMedica in a report on Friday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $16.00.

Insiders Place Their Bets

In other CalciMedica news, insider Sudarshan Hebbar acquired 9,563 shares of CalciMedica stock in a transaction on Tuesday, August 19th. The shares were bought at an average price of $2.82 per share, with a total value of $26,967.66. Following the completion of the purchase, the insider owned 61,539 shares in the company, valued at $173,539.98. This trade represents a 18.40% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Eric W. Roberts bought 9,200 shares of the company’s stock in a transaction dated Thursday, August 28th. The shares were purchased at an average price of $2.86 per share, with a total value of $26,312.00. Following the transaction, the insider owned 70,107 shares of the company’s stock, valued at $200,506.02. The trade was a 15.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 50,366 shares of company stock worth $144,317. Insiders own 41.55% of the company’s stock.

CalciMedica Price Performance

CalciMedica stock opened at $3.01 on Monday. The company has a debt-to-equity ratio of 1.39, a current ratio of 5.45 and a quick ratio of 5.45. The company has a market capitalization of $42.05 million, a PE ratio of -1.88 and a beta of 1.34. CalciMedica Inc. has a one year low of $1.42 and a one year high of $5.65. The business has a 50 day simple moving average of $3.09 and a 200 day simple moving average of $2.42.

CalciMedica (NASDAQ:CALC) last posted its earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, hitting the consensus estimate of ($0.40). On average, sell-side analysts forecast that CalciMedica Inc. will post -2.21 EPS for the current fiscal year.

CalciMedica Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.